Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Boron-doped CQDs (B-CQDs), namely Formulation 1 (F1) and Formulation 2 (F2), preserved greater than 86% viability across multiple cell lines, demonstrating organ-specific targeting capabilities relevant to bioimaging and drug delivery strategies [ Syzygium malaccense -derived CQDs (SM-CQDs) exhibited weak cytotoxicity in 3T3-L1 adipocytes, with an IC 50 of 444.5 g/mL, while enhancing glucose uptake, reflecting their promise as biocompatible nanomaterials for metabolic and therapeutic applications [160]
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
May repair muscles, tendons, and ligaments
It plays a key role in red blood cell production, DNA synthesis, and nerve function
US$ 25.00
US$ 22.63
US$ 22.42
US$ 24.94
US$ 22.50
US$ 22.96
US$ 28.08
US$ 25.37
US$ 22.39
